Oral azithromycin in extended dosage schedule for chronic, subclinical Chlamydia pneumoniae infection causing coronary artery disease: A probable cure in sight? Results of a controlled preliminary trial

International Journal of General Medicine

Volumn 5, Issue , 2012, Pages 505-509

  Dogra, Jaideep ^a  

^a Central Government Health Scheme   (India)

Author keywords

Azithromycin; Chlamydia pneumoniae; Coronary artery disease

Indexed keywords

AZITHROMYCIN; C REACTIVE PROTEIN; CREATININE; IMMUNOGLOBULIN G ANTIBODY;

ADULT; ANGINA PECTORIS; ANTIBODY TITER; ARTICLE; ASYMPTOMATIC INFECTION; CHLAMYDIAL PNEUMONIA; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIARRHEA; ERYTHROCYTE PARAMETERS; FEMALE; GASTRIC INTOLERANCE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; LIVER FUNCTION TEST; LONG TERM CARE; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; PERCUTANEOUS CORONARY INTERVENTION; RECURRENT DISEASE; SECONDARY PREVENTION; STOMACH DISEASE; TREATMENT DURATION;

EID: 84877131201     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S31625     Document Type: Article

References (31)

1. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336(8719):827-830.
2. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344(25):1879-1887.
3. Schwartz GG, Olsson AG, Ezckowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711-1718.
4. Mattila K. Viral and bacterial infections in patients with acute myocardial infarction. J Intern Med. 1989;225(5):293-296.
5. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J. 1992;82(3):158-161.
6. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis. 1993;167(4):841-849.
7. Fong IW, Chiu B, Viira E, Fong MW, Jang D, Mahony J. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol. 1997;35(1):48-52.
8. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998;97(7):633-636.
9. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med. 1995;333(15):984-991.
10. Saxena VN, Dogra J. Long-term use of penicillin for the treatment of chronic plaque psoriasis. Eur J Dermatol. 2005;15(5):359-362.
11. Taylor-Robinson D, Thomas BJ. Chlamydia pneumoniae in arteries: the facts, their interpretation, and future studies. J Clin Pathol. 1998;51(11):793-797.
12. O'Connor CM, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA. 2003;290(11):1459-1466.
13. Grayston JT, Kronmal RA, Jackson LA, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352(16):1637-1645.
14. Cannon CP, Braunwald E, McCabe CH, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005;352(16):1646-1654.
15. Anderson J. Infection, antibiotics, and atherothrombosis-end of the road or new beginnings? N Engl J Med. 2005;352(16):1706-1709.
16. Wolter J, Seeney S, Bell S, Bowler S, Masel T, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomized trial. Thorax. 2002;57(3):212-216.
17. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749-1756.
18. Oldfield EC 3rd, Fessel WJ, Dunne MW, et al. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clin Infect Dis. 1998;26(3):611-619.
19. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med. 1996;335(6):392-398.
20. Saxena VN, Dogra J. Long-term oral azithromycin in chronic plaque psoriasis: a controlled trial. Eur J Dermatol. 2010;20(3):329-333.
21. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350(9075):430-436.
22. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA. 1992;268(1):68-72.
23. Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B. Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. Circulation. 2002;106(19):2428-2433.
24. Vammen S, Lindholt JS, Ostergaard L, Fasting H, Henneberg EW. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg. 2001;88(8):1066-1072.
25. Wiesli P, Czerwenka W, Meniconi A, et al. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized, double-blind, placebo-controlled trial. Circulation. 2002;105(22):2646-2652.
26. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735-1741.
27. Visser MR, Tracy PB, Vercelotti GM, Goodman JL, White JG, Jacob HS. Enhanced thrombin generation and platelet binding on herpes simplex virus-infected endothelium. Proc Natl Acad Sci U S A. 1988;85(21):8227-8230.
28. Fabricant CG, Hajjar DP, Minick CR, Fabricant J. Herpesvirus infection enhances cholesterol and cholesteryl ester accumulation in cultured arterial smooth muscle cells. Am J Pathol. 1981;105(2):176-184.
29. Lopes-Virella MF, Virella G. Immunological and microbiological factors in the pathogenesis of atherosclerosis. Clin Immunol Immunopathol. 1985;37(3):377-386.
30. Sammalkorpi K, Valtonen V, Kerttula Y, Nikkila E, Taskinen MR. Changes in serum lipoprotein pattern induced by acute infections. Metabolism. 1988;37(9):859-865.
31. Grayston JT. Antibiotic treatment of Chlamydia pneumoniae for secondary prevention of cardiovascular events. Circulation. 1998;97(17):1669-1670.